why choose us

First received: March 21, 2023

Clinical Trial: A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Breast Cancer Metastatic

Study Type: INTERVENTIONAL


Official Title: A Phase 1-2 Dose-escalation and Expansion Study of ST316 in Subjects With Selected Advanced Unresectable and Metastatic Solid Tumors

Brief Summary: This is an open-label, two-part, phase 1-2 study designed to determine the safety, tolerability, PK, pharmacodynamics (PD), and proof-of-concept efficacy of ST316 administered IV in subjects with selected advanced solid tumors likely to harbor abnormalities of the WNT/?-catenin signaling pathway.The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.

Read more